Hepatitis C virus-human immunodeficiency virus coinfection

Area of Science:

• Hepatology
• Infectious Diseases
• Virology

Background:

• Chronic hepatitis C virus (HCV) infection is prevalent in HIV-infected individuals due to shared transmission routes.
• HCV infection is a leading cause of illness and death globally, especially in the context of effective antiretroviral therapy for HIV.
• Peginterferon (PEG-IFN) plus ribavirin (RBV) has been the standard treatment for coinfected patients at high risk for liver disease, but with disappointing results.

Purpose of the Study:

• To evaluate the effectiveness and safety of novel HCV NS3/4A protease inhibitors (telaprevir and boceprevir) in patients coinfected with HIV and HCV.
• To assess the potential for drug interactions and toxicities associated with these new agents in the coinfected population.

Main Methods:

• Limited clinical data were analyzed regarding the use of telaprevir and boceprevir.
• Treatment regimens included combination therapy with PEG-IFN/RBV alongside protease inhibitors.
• Patient outcomes focused on viral suppression rates, toxicity profiles, and drug-drug interactions.

Main Results:

• Limited data suggest that telaprevir and boceprevir, when added to PEG-IFN/RBV, enhance viral suppression rates in coinfected patients.
• The combination therapy demonstrated a manageable toxicity and drug-drug interaction profile.
• These findings indicate potential efficacy for protease inhibitors in this challenging patient group.

Conclusions:

• HCV NS3/4A protease inhibitors (telaprevir, boceprevir) may offer improved treatment outcomes for HIV/HCV coinfected patients.
• Careful selection of patients is crucial for optimizing treatment with these agents.
• Further research is warranted to fully establish the role of protease inhibitors in managing HCV in HIV-infected populations.